Clinical Trials List
2009-10-01 - 2012-01-31
Phase I/II
Study ended10
ICD-10C22.9
Malignant neoplasm of liver, not specified as primary or secondary
ICD-10Z51.12
Encounter for antineoplastic immunotherapy
ICD-9155.2
Malignant neoplasm of liver, not specified as primary or secondary
-
Trial Applicant
Boehringer Ingelheim
-
Sponsor
-
Trial scale
Multi-Regional Multi-Center
-
Update
2025/08/20
Investigators and Locations
Co-Principal Investigator
- PEI-JER CHEN Division of Hematology & Oncology
- Chih-Hung Hsu Division of Hematology & Oncology
- Ying-Chun Shen Division of Hematology & Oncology
- Chiun Hsu Division of Hematology & Oncology
- 林宗哲 Division of Hematology & Oncology
The Actual Total Number of Participants Enrolled
0 Study ended
Co-Principal Investigator
- Chia-Jui Yen Division of Hematology & Oncology
- 夏和雄 Division of Hematology & Oncology
- Peng-Chan Lin Division of Hematology & Oncology
- Wen-Pin Su Division of Hematology & Oncology
- Li-Tzong Chen Division of Hematology & Oncology
The Actual Total Number of Participants Enrolled
0 Study ended
Co-Principal Investigator
The Actual Total Number of Participants Enrolled
0 Study ended
The Actual Total Number of Participants Enrolled
0 Study ended
Co-Principal Investigator
The Actual Total Number of Participants Enrolled
0 Study ended
Co-Principal Investigator
The Actual Total Number of Participants Enrolled
0 Study ended
Co-Principal Investigator
The Actual Total Number of Participants Enrolled
0 Study ended
Co-Principal Investigator
The Actual Total Number of Participants Enrolled
0 Study ended
Co-Principal Investigator
- Jing-Houng Wang Digestive System Department
The Actual Total Number of Participants Enrolled
0 Study ended
Co-Principal Investigator
- Wan-Long Chuang Digestive System Department
The Actual Total Number of Participants Enrolled
0 Study ended
Condition/Disease
Objectives
Test Drug
Active Ingredient
Dosage Form
Dosage
Endpoints
Inclution Criteria
The Estimated Number of Participants
-
Taiwan
60 participants
-
Global
90 participants
